Skip to main content
Glama

Clinicaltrials

by io.github.pipeworx-io

Entity Profile

entity_profile
Read-onlyIdempotent

"Tell me about X" / "research Acme" / "brief me on Tesla" / "what does Apple do" / "company profile for Microsoft" / "give me the rundown on NVDA" / "everything you know about $TICKER" — full cross-source profile of a US public company in ONE parallel call. ALWAYS PREFER over chaining single-pack SEC/XBRL/news lookups when the user asks for a holistic view. Fans out across SEC EDGAR, XBRL, USPTO patents, federal contracts (USAspending), FDA-licensed biologics (Purple Book), H-1B hiring (DOL LCA), news and GLEIF, and returns: cik + company_name (+ resolved_from/resolved_to when value was a name); recent_filings (up to 5 with pipeworx://edgar/company/{cik}/filings/{accession} URIs); fundamentals (LATEST 10-K Revenues + NetIncomeLoss + Cash, sorted period_end DESC); patents (USPTO PatentsView API sunset May 2025 — soft-fails until reactivated); federal_contracts (USAspending awards where the company is the recipient); fda_products (FDA-licensed biologics — vaccines, cell/gene therapies — from the Purple Book; a company with only small-molecule/generic drugs will show none here, that is expected, not a failure); hiring (H-1B sponsorship volume + salary range from DOL LCA filings); recent news mentions via GDELT→GNews fallback; LEI via GLEIF. sources_used / sources_failed say which of these actually returned data for THIS company — an empty section is a real "no data", not a bug. Pass a ticker ("AAPL"), zero-padded CIK ("0000320193"), OR a company name ("Moderna") — names now resolve via SEC EDGAR's company-name match; a private company (no CIK/ticker) returns resolved:false with an explicit notes line, not a bare failure. type accepts "company" or "ticker" interchangeably — both take the same value shapes above.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYes"company" or "ticker" — both are accepted and behave identically; `value` can be a ticker, CIK, or company name either way. person/place coming soon.
valueYesTicker (e.g., "AAPL"), zero-padded CIK (e.g., "0000320193"), or company name (e.g., "Moderna") — names resolve via SEC EDGAR company-name match.

TDQS

A4.9/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already indicate readOnly, openWorld, idempotent, non-destructive. The description adds significant behavioral context: fans across multiple sources, returns specific data fields (CIK, filings, fundamentals, patents, news, LEI), notes that patents source may sunset May 2025 and soft-fails, and mentions fallback from GDELT to GNews. No contradictions.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is relatively long but every sentence adds value. It front-loads example queries and key usage advice. Minor redundancy in listing data sources could be trimmed, but overall efficient for the information density.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Given the tool has only two simple parameters and no output schema, the description adequately explains what the tool returns (with specific fields and limitations) and edge cases (patents sunset, name not supported). It is complete enough for an AI agent to use correctly.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100% with descriptions. The description adds value by providing concrete examples ('AAPL', '0000320193'), clarifying that names are not supported, and explaining that type is currently limited to 'company'. This goes beyond schema alone.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description clearly states it creates a full cross-source profile of a US public company in one parallel call, with specific examples ('tell me about X', 'research Acme'). It distinguishes from siblings like resolve_entity by noting names are not supported, and from other tools by emphasizing it should be preferred over chaining single-source lookups.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines5/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description explicitly says 'ALWAYS PREFER over chaining single-pack SEC/XBRL/news lookups' and advises using resolve_entity if only a name is available. This provides clear when-to-use and when-not-to-use guidance.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Clinicaltrials toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.6/5.0
Disambiguation1/5

Several tools appear to do the same thing at the top level: ask_pipeworx, ask_pipeworx_beta (explicitly identical today), and ask_pipeworx_grounded are near-duplicate routing entry points, and deep_research overlaps heavily with them. Among the ct_* tools, ct_count_by_condition, ct_competitive_landscape, ct_sponsor_pipeline, and ct_compare_sponsors all provide overlapping counting/landscape functionality, making correct selection genuinely ambiguous.

Naming Consistency4/5

The overwhelming majority of tools use lowercase snake_case and mostly follow a verb_noun or domain-prefixed pattern (ct_search, ct_get_study, list_subscriptions, validate_claim, resolove_entity). Some names are noun phrases rather than verbs (ct_competitive_landscape, entity_profile, polymarket_edge_tracker) but the overall style is consistent and readable, with only minor deviations.

Tool Count2/5

44 tools is far too many for a server named 'Clinicaltrials'; only 13 tools are actually clinical-trials-specific while the rest span general data lookup, prediction markets, memory, subscriptions, and npm scanning. The count is inflated by redundant entry points (ask_pipeworx/beta/grounded) and overlapping ct tools, making the set feel heavy and unfocused.

Completeness4/5

For the clinical-trials registry domain, the surface is largely complete: search, full study details, results summaries, condition counts, sponsor pipelines, location-based lookup, recent updates, and catalyst tracking are all represented. Minor gaps exist (e.g., historical versions/protocol amendments and advanced filter combinations), but most could be worked around via the universal ask_pipeworx router.

Resources